vladgrin-shutterstock-com
VLADGRIN / Shutterstock.com
1 March 2016PharmaGareth Morgan

Waiving goodbye to SPC rights

At perhaps no other time during the 20-year lifespan of the supplementary protection certificate (SPC) has more legislative attention been given to determining whether it is fit for purpose. Other key questions concern whether the encroachment of heightened levels of regulation into industrial sectors other than pharmaceuticals and agrichemicals justifies similar intellectual property right ‘top up’ regimes being put in place.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
Pharma
21 August 2026   Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
Pharma
20 August 2026   A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.